Bicycle Therapeutics Announces Positive Topline Results from Oxurion’s Phase I Trial Using a Novel Bicycle-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
Phase I results provide additional clinical activity data for Bicycles CAMBRIDGE, U.K., & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics, a biotechnology company pioneering…